Ignite Creation Date:
2024-05-05 @ 11:32 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00072683
Status:
COMPLETED
Last Update Posted:
2007-01-26
First Post:
2003-11-07
Brief Title:
SALT Trial Study of Ascending Levels of Tolvaptan in Hyponatremia
Sponsor:
Otsuka Pharmaceutical Development Commercialization Inc
Organization:
Otsuka Pharmaceutical Development Commercialization Inc
Study Overview
Official Title:
Multicenter Randomized Double-Blind Placebo-Controlled Efficacy and Safety Study of the Effects of Titrated Oral Tolvaptan Tablets in Patients With Hyponatremia
Status:
COMPLETED
Status Verified Date:
2007-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This studys purpose is to determine whether tolvaptan can safely and effectively return the bodys balance of sodium and water toward normal and to characterize and quantify the potential clinical benefits of this treatment
Detailed Description:
Hyponatremia is defined as a serum sodium concentration below the lower limit of normal and is the most frequently encountered electrolyte abnormality in hospitalized patients Generally speaking most cases of hyponatremia are mild However as the serum sodium falls below 130 mEqL the possibility of significant morbidity and mortality increases and most clinicians will initiate corrective therapy for serum sodium values approaching 130 mEqL and lower The reasons for treating hyponatremia relate both to the symptoms which may be quite disturbing to patients as well as to potential outcomes including permanent neurological damage and death There is also growing awareness of the association between hyponatremia and increased mortality in patients with heart failureA common theme underlying the occurrence of hyponatremia whether in the setting of congestive heart failure hepatic failure with ascites or the syndrome of inappropriate anti-diuretic hormone SIADH is the non-osmotic secretion of arginine vasopressin AVP The presence of excess AVP leads to fluid retention and hyponatremia Agents that antagonize AVP causing proportionally more water diuresis than solute excretion could offer a significant treatment option for patients with hyponatremia compared to fluid restriction alone Treatment of hyponatremia particularly in clinical settings such as decompensated congestive heart failure is difficult as conventional diuretics cause neurohormonal activation and further stimulate the inappropriate release of vasopressin leading to additional retention of free water and aggravation of hypoosmolality Similarly for cirrhosis with ascites and SIADH conventional diuretics are either minimally effective or completely contraindicated An alternative approach to symptom relief and treatment of hyponatremia may be the use of vasopressin antagonists which increase free water clearance with proportionally less effect on sodium excretion Tolvaptan is an oral vasopressin antagonist with relative affinity for the V2 receptor which has been shown to induce a diuresis with proportionally more free-water than sodium loss The current study is being undertaken in order to evaluate whether tolvaptan an oral AVP inhibitor will be effective in correcting mild to moderate hyponatremia and to elucidate the effect of this correction on the subjects well-being
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None